

Takaomi Sanda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7957286/publications.pdf>

Version: 2024-02-01

86
papers

6,760
citations

87843

38
h-index

64755

79
g-index

87
all docs

87
docs citations

87
times ranked

12288
citing authors

#	ARTICLE	IF	CITATIONS
1	Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma. <i>Cancer Research</i> , 2022, 82, 406-418.	0.4	18
2	IRF4 drives clonal evolution and lineage choice in a zebrafish model of T-cell lymphoma. <i>Nature Communications</i> , 2022, 13, 2420.	5.8	5
3	Loss of METTL3 attenuates blastic plasmacytoid dendritic cell neoplasm response to PRMT5 inhibition via IFN signaling. <i>Blood Advances</i> , 2022, 6, 5330-5344.	2.5	2
4	Oncorequisite role of an aldehyde dehydrogenase in the pathogenesis of T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, 106, 1545-1558.	1.7	2
5	Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 32.	2.8	14
6	Super-enhancers for RUNX3 are required for cell proliferation in EBV-infected B cell lines. <i>Gene</i> , 2021, 774, 145421.	1.0	9
7	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	20
8	Sphingosine 1-Phosphate Receptor 2 Induces Otoprotective Responses to Cisplatin Treatment. <i>Cancers</i> , 2020, 12, 211.	1.7	22
9	Feed-forward regulatory loop driven by IRF4 and NF- κ B in adult T-cell leukemia/lymphoma. <i>Blood</i> , 2020, 135, 934-947.	0.6	28
10	Super-Enhancer-Driven TOX2 Mediates Oncogenesis in Natural Killer/T Cell Lymphoma. <i>Blood</i> , 2020, 136, 17-17.	0.6	1
11	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. <i>Leukemia</i> , 2019, 33, 696-709.	3.3	40
12	Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2019, 109, 5-17.	0.7	25
13	The enhancer RNA ARIEL activates the oncogenic transcriptional program in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2019, 134, 239-251.	0.6	54
14	Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1350-1357.	3.0	32
15	ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry. <i>Nature Communications</i> , 2019, 10, 5622.	5.8	56
16	Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2018, 32, 2138-2151.	3.3	38
17	JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 1929-1945.	4.2	22
18	Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma. <i>Haematologica</i> , 2018, 103, 2059-2068.	1.7	14

#	ARTICLE	IF	CITATIONS
19	Targeting General Transcriptional Machinery as a Therapeutic Strategy for Adult T-Cell Leukemia. <i>Molecules</i> , 2018, 23, 1057.	1.7	9
20	APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL. <i>Leukemia</i> , 2017, 31, 2057-2064.	3.3	54
21	Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2017, 177, 271-282.	1.2	28
22	Roles of the RUNX1 Enhancer in Normal Hematopoiesis and Leukemogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2017, 962, 139-147.	0.8	15
23	Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2017, 31, 1798-1807.	3.3	28
24	Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia. <i>Blood</i> , 2017, 130, 2326-2338.	0.6	66
25	RUNX1 in T-ALL: tumor suppressive or oncogenic?. <i>Blood</i> , 2017, 130, 1686-1688.	0.6	4
26	TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia. <i>Experimental Hematology</i> , 2017, 53, 7-15.	0.2	41
27	ARID5B as a critical downstream target of the TAL1 complex that activates the oncogenic transcriptional program and promotes T-cell leukemogenesis. <i>Genes and Development</i> , 2017, 31, 2343-2360.	2.7	51
28	Leukemia-Initiating Cells in T-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2017, 7, 218.	1.3	32
29	The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis. <i>Leukemia</i> , 2016, 30, 1365-1374.	3.3	44
30	The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. <i>Nature Communications</i> , 2016, 7, 10258.	5.8	87
31	HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2016, 30, 219-228.	3.3	36
32	TRIB2 reinforces the oncogenic transcriptional program controlled by the TAL1 complex in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2016, 30, 959-962.	3.3	17
33	Abstract 1180: The TCA cycle transferase DLST is critical for MYC-mediated leukemogenesis. , 2016, , .		1
34	Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2249-2259.	1.9	53
35	An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. <i>Science</i> , 2014, 346, 1373-1377.	6.0	665
36	Ribonucleoprotein HNRNPA2B1 Interacts With and Regulates Oncogenic KRAS in Pancreatic Ductal Adenocarcinoma Cells. <i>Gastroenterology</i> , 2014, 147, 882-892.e8.	0.6	56

#	ARTICLE	IF	CITATIONS
37	Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. <i>Nature</i> , 2014, 511, 616-620.	13.7	698
38	BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines. <i>Leukemia</i> , 2014, 28, 1145-1148.	3.3	38
39	RUNX1 point mutations potentially identify a subset of early immature T-cell acute lymphoblastic leukaemia that may originate from differentiated T-cells. <i>Gene</i> , 2014, 545, 111-116.	1.0	9
40	Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in <i>ALK</i> -mutated neuroblastoma. <i>Oncotarget</i> , 2014, 5, 8737-8749.	0.8	72
41	<i>KPT-330</i> inhibitor of <i>CRM1</i> (<i>XPO1</i>)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of <i>T</i> -cell acute lymphoblastic leukaemia and acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013, 161, 117-127.	1.2	149
42	Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer. <i>ACS Chemical Biology</i> , 2013, 8, 1423-1428.	1.6	40
43	TYK2-STAT1-BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2013, 3, 564-577.	7.7	122
44	The TAL1 complex targets the <i>FBXW7</i> tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2013, 210, 1545-1557.	4.2	107
45	Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. <i>Leukemia</i> , 2013, 27, 66-74.	3.3	166
46	HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase. <i>Blood</i> , 2013, 122, 2528-2528.	0.6	0
47	A Genetic Screen In Zebrafish Identified <i>Dlst</i> As a Potential Therapeutic Target For Human Acute T-Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 1273-1273.	0.6	0
48	Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. <i>Leukemia</i> , 2012, 26, 2233-2244.	3.3	64
49	Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. <i>Nature Medicine</i> , 2012, 18, 1118-1122.	15.2	162
50	Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics. <i>Journal of Biological Chemistry</i> , 2012, 287, 9742-9752.	1.6	89
51	The Requirement for Cyclin D Function in Tumor Maintenance. <i>Cancer Cell</i> , 2012, 22, 438-451.	7.7	284
52	Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in Human T Cell Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2012, 22, 209-221.	7.7	262
53	PIDD Death-Domain Phosphorylation by ATM Controls Prodeath versus Prosurvival PIDDosome Signaling. <i>Molecular Cell</i> , 2012, 47, 681-693.	4.5	78
54	The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma. <i>Cancer Cell</i> , 2012, 22, 117-130.	7.7	270

#	ARTICLE	IF	CITATIONS
55	TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 1470-1470.	0.6	1
56	The TAL1 Complex Represses the FBXW7 Tumor Suppressor Through Mir-223 in Human T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 1296-1296.	0.6	0
57	Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. <i>Journal of Experimental Medicine</i> , 2011, 208, 663-675.	4.2	106
58	The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 4169-4173.	0.6	162
59	KPT-SINE, a Potent, Small Molecule Inhibitor of CRM1-Dependent Nuclear-Cytoplasmic Shuttling, with Potent Activity Against T-ALL and AML. <i>Blood</i> , 2011, 118, 2622-2622.	0.6	8
60	Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011, 118, 3453-3453.	0.6	0
61	Combined Targeting of the MET and FGF Receptor Tyrosine Kinases Induces Sustained AML Cell Death by Preventing Compensatory Upregulation of HGF in Response to MET Kinase Inhibition. <i>Blood</i> , 2011, 118, 1405-1405.	0.6	2
62	Mutationally Activated TYK2 From T-ALL Specimens Exhibits Transformative Capacity in Cell Lines and Primary Cell Models and T-Lineage Expansion in Mice. <i>Blood</i> , 2011, 118, 74-74.	0.6	14
63	Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 2845-2851.	0.6	112
64	Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 1735-1745.	0.6	61
65	T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation. <i>Cancer Cell</i> , 2010, 18, 353-366.	7.7	141
66	ATM-deficient thymic lymphoma is associated with aberrant <i>tcrd</i> rearrangement and gene amplification. <i>Journal of Experimental Medicine</i> , 2010, 207, 1369-1380.	4.2	74
67	Phosphatase-Dependent and -Independent Functions of Shp2 in Neural Crest Cells Underlie LEOPARD Syndrome Pathogenesis. <i>Developmental Cell</i> , 2010, 18, 750-762.	3.1	96
68	Absence of Biallelic <i>TCRβ</i> Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3816-3823.	0.8	93
69	Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 3155-3155.	0.6	0
70	The BCL11B Tumor Suppressor Is Mutated In Human T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 4177-4177.	0.6	0
71	Aberrant Expression of Hepatocyte Growth Factor Induces Autocrine MET Activation Providing a Novel Therapeutic Target In Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 1042-1042.	0.6	1
72	High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2009, 114, 647-650.	0.6	414

#	ARTICLE	IF	CITATIONS
73	Emi1 Maintains Genomic Integrity during Zebrafish Embryogenesis and Cooperates with p53 in Tumor Suppression. <i>Molecular and Cellular Biology</i> , 2009, 29, 5911-5922.	1.1	33
74	Activating mutations in ALK provide a therapeutic target in neuroblastoma. <i>Nature</i> , 2008, 455, 975-978.	13.7	775
75	Overexpression of carboxylesterase ϵ 2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT ϵ 1), for multiple myeloma. <i>Cancer Science</i> , 2008, 99, 2309-2314.	1.7	33
76	Induction of class II major histocompatibility complex expression in human multiple myeloma cells by retinoid. <i>Haematologica</i> , 2007, 92, 115-120.	1.7	8
77	Knock down of hSNF5/Ini1 causes cell cycle arrest and apoptosis in a p53-dependent manner. <i>Biochemical and Biophysical Research Communications</i> , 2007, 361, 580-585.	1.0	14
78	Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. <i>Leukemia</i> , 2007, 21, 2344-2353.	3.3	40
79	Transcription Factors as Therapeutic Targets in Lymphoid Malignancies. <i>International Reviews of Immunology</i> , 2007, 26, 305-332.	1.5	3
80	Induction of cell death in adult T-cell leukemia cells by a novel I ϵ B kinase inhibitor. <i>Leukemia</i> , 2006, 20, 590-598.	3.3	47
81	Severe Hypercholesterolemia Associated with Decreased Hepatic Triglyceride Lipase Activity and Pseudohyponatremia in Patients after Allogeneic Stem Cell Transplantation. <i>International Journal of Hematology</i> , 2005, 82, 362-366.	0.7	15
82	Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis. <i>Leukemia</i> , 2005, 19, 901-909.	3.3	26
83	Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon- γ (MIG) gene expression in B-cell malignancy. <i>Leukemia</i> , 2005, 19, 1471-1478.	3.3	26
84	Growth Inhibition of Multiple Myeloma Cells by a Novel I ϵ B Kinase Inhibitor. <i>Clinical Cancer Research</i> , 2005, 11, 1974-1982.	3.2	68
85	RNA helicase ϵ fA interacts with nuclear factor I ϵ B p65 and functions as a transcriptional coactivator. <i>FEBS Journal</i> , 2004, 271, 3741-3751.	0.2	77
86	Successful Treatment of Nasal T-Cell Lymphoma With a Combination of Local Irradiation and High-Dose Chemotherapy. <i>International Journal of Hematology</i> , 2002, 75, 195-200.	0.7	11